Korean precision diagnostic testing firm NGeneBio joins CancerX partnership

South Korea’s precision diagnostic platform company NGeneBio Co. announced its membership in CancerX, a public-private partnership led by The White House as a national accelerator to boost innovation in the fight against cancer as part of the Cancer Moonshot initiative.

The Cancer Moonshot initiative aims to invest an annual $1.8 billion in various oncology fields to provide digital innovation and application methods to improve the equity of cancer treatment and research.

This program has garnered participation from global pharmaceutical and healthcare companies such as Johnson & Johnson and Takeda, as well as tech giants like Intel and Amazon.

NGeneBio has commercialized the NGeneAnalySys, a precision cancer diagnostic platform that consists of genetic diagnostic panels for breast cancer, solid tumors, and blood cancers, coupled with data analysis software.

As a member of CancerX, NGeneBio will collaborate with global companies and institutions to develop artificial intelligence (AI) capabilities for early cancer detection.

CancerX represents international cooperation and collective effort towards advancing cancer research and treatment, bridging the gap between public and private sectors to accelerate progress in the fight against cancer.